中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝门部胆管癌手术切缘的研究进展

王艺睿 刘硕琛 李相成

王艺睿, 刘硕琛, 李相成. 肝门部胆管癌手术切缘的研究进展[J]. 临床肝胆病杂志, 2021, 37(11): 2742-2744. DOI: 10.3969/j.issn.1001-5256.2021.11.056.
引用本文: 王艺睿, 刘硕琛, 李相成. 肝门部胆管癌手术切缘的研究进展[J]. 临床肝胆病杂志, 2021, 37(11): 2742-2744. DOI: 10.3969/j.issn.1001-5256.2021.11.056.
WANG YR, LIU SC, LI XC. Research advances in surgical margin of hilar cholangiocarcinoma[J]. J Clin Hepatol, 2021, 37(11): 2742-2744. DOI: 10.3969/j.issn.1001-5256.2021.11.056.
Citation: WANG YR, LIU SC, LI XC. Research advances in surgical margin of hilar cholangiocarcinoma[J]. J Clin Hepatol, 2021, 37(11): 2742-2744. DOI: 10.3969/j.issn.1001-5256.2021.11.056.

肝门部胆管癌手术切缘的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.11.056
基金项目: 

江苏省重点病种规范化诊疗研究项目 BE2016789;

国家自然科学基金 81670570

详细信息
    通信作者:

    李相成,drxcli@njmu.edu.cn

  • 中图分类号: R735.8

Research advances in surgical margin of hilar cholangiocarcinoma

Research funding: 

Project of Standardized Diagnosis and Treatment of Key Diseases in Jiangsu Province BE2016789;

National Natural Science Foundation of China 81670570

  • 摘要: 肝门部胆管癌是最常见的胆道肿瘤,外科手术仍是目前唯一可能有效的治疗方法。手术切缘的性质是患者长期预后的重要影响因素,根治性切除可使患者获得极大的生存获益。肝门部胆管癌环周切缘的评估,有助于更精准地判断切缘性质和预测患者预后。现对肝门部胆管癌的手术切缘最新研究进展进行综述。

     

  • [1] RIZVI S, KHAN SA, HALLEMEIER CL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2): 95-111. DOI: 10.1038/nrclinonc.2017.157.
    [2] SAHA SK, ZHU AX, FUCHS CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S. : Intrahepatic disease on the rise[J]. Oncologist, 2016, 21(5): 594-599. DOI: 10.1634/theoncologist.2015-0446.
    [3] BANALES JM, MARIN J, LAMARCA A, et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(9): 557-588. DOI: 10.1038/s41575-020-0310-z.
    [4] KHAN AS, DAGEFORDE LA. Cholangiocarcinoma[J]. Surg Clin North Am, 2019, 99(2): 315-335. DOI: 10.1016/j.suc.2018.12.004.
    [5] LI XC, FENG QC. Advance and controversy of hilar cholangiocarcinoma[J]. J Clin Hepatol, 2019, 35(12): 2632-2637. DOI: 10.3969/j.issn.1001-5256.2019.12.004.

    李相成, 冯勤超. 肝门部胆管癌的进展与争议[J]. 临床肝胆病杂志, 2019, 35(12): 2632-2637. DOI: 10.3969/j.issn.1001-5256.2019.12.004.
    [6] FORNER A, VIDILI G, RENGO M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma[J]. Liver Int, 2019, 39(Suppl 1): 98-107. DOI: 10.1111/liv.14086.
    [7] SAKAMOTO Y, KOSUGE T, SHIMADA K, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: An analysis of 55 patients concerning the significance of ductal and radial margins[J]. Surgery, 2005, 137(4): 396-402. DOI: 10.1016/j.surg.2004.10.008.
    [8] MANTEL HT, WESTERKAMP AC, SIEDERS E, et al. Intraoperative frozen section analysis of the proximal bile ducts in hilar cholangiocarcinoma is of limited value[J]. Cancer Med, 2016, 5(7): 1373-1380. DOI: 10.1002/cam4.693.
    [9] SHINOHARA K, EBATA T, SHIMOYAMA Y, et al. A study on radial margin status in resected perihilar cholangiocarcinoma[J]. Ann Surg, 2021, 273(3): 572-578. DOI: 10.1097/SLA.0000000000003305.
    [10] STREMITZER S, STIFT J, LAENGLE J, et al. Prognosis and circumferential margin in patients with resected hilar cholangiocarcinoma[J]. Ann Surg Oncol, 2021, 28(3): 1493-1498. DOI: 10.1245/s10434-020-09105-1.
    [11] AHMAD J, LOUGHREY MB, DONNELLY D, et al. Prognostic value of added stratification of circumferential resection margin status in oesophageal carcinoma[J]. Histopathology, 2013, 62(5): 752-763. DOI: 10.1111/his.12078.
    [12] BUETTNER S, MARGONIS GA, KIM Y, et al. Conditional probability of long-term survival after resection of hilar cholangiocarcinoma[J]. HPB (Oxford), 2016, 18(6): 510-517. DOI: 10.1016/j.hpb.2016.04.001.
    [13] RIBERO D, PINNA AD, GUGLIELMI A, et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis of 434 patients[J]. Arch Surg, 2012, 147(12): 1107-1113. DOI: 10.1001/archsurg.2012.1962.
    [14] de JONG MC, MARQUES H, CLARY BM, et al. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: A multi-institutional analysis of 305 cases[J]. Cancer, 2012, 118(19): 4737-4747. DOI: 10.1002/cncr.27492.
    [15] SHINGU Y, EBATA T, NISHIO H, et al. Clinical value of additional resection of a margin-positive proximal bile duct in hilar cholangiocarcinoma[J]. Surgery, 2010, 147(1): 49-56. DOI: 10.1016/j.surg.2009.06.030.
    [16] LI CX, ZHANG H, WANG K, et al. Preoperative bilirubin level predicts overall survival and tumor recurrence after resection for perihilar cholangiocarcinoma patients[J]. Cancer Manag Res, 2019, 11: 10157-10165. DOI: 10.2147/CMAR.S230620.
    [17] KOMAYA K, EBATA T, YOKOYAMA Y, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: Analysis of a large cohort with a close postoperative follow-up approach[J]. Surgery, 2018, 163(4): 732-738. DOI: 10.1016/j.surg.2017.08.011.
    [18] ZHANG XF, SQUIRES MH 3rd, BAGANTE F, et al. The impact of intraoperative re-resection of a positive bile duct margin on clinical outcomes for hilar cholangiocarcinoma[J]. Ann Surg Oncol, 2018, 25(5): 1140-1149. DOI: 10.1245/s10434-018-6382-0.
    [19] OGURO S, ESAKI M, KISHI Y, et al. Optimal indications for additional resection of the invasive cancer-positive proximal bile duct margin in cases of advanced perihilar cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22(6): 1915-1924. DOI: 10.1245/s10434-014-4232-2.
    [20] GOVIL S, REDDY MS, RELA M. Surgical resection techniques for locally advanced hilar cholangiocarcinoma[J]. Langenbecks Arch Surg, 2014, 399(6): 707-716. DOI: 10.1007/s00423-014-1216-4.
    [21] PORUK KE, PAWLIK TM, WEISS MJ. Perioperative management of hilar cholangiocarcinoma[J]. J Gastrointest Surg, 2015, 19(10): 1889-1899. DOI: 10.1007/s11605-015-2854-8.
    [22] SOARES KC, KAMEL I, COSGROVE DP, et al. Hilar cholangiocarcinoma: Diagnosis, treatment options, and management[J]. Hepatobiliary Surg Nutr, 2014, 3(1): 18-34. DOI: 10.3978/j.issn.2304-3881.2014.02.05.
    [23] WEISS MJ, COSGROVE D, HERMAN JM, et al. Multimodal treatment strategies for advanced hilar cholangiocarcinoma[J]. Langenbecks Arch Surg, 2014, 399(6): 679-692. DOI: 10.1007/s00423-014-1219-1.
    [24] CHATELAIN D, FARGES O, FUKS D, et al. Assessment of pathology reports on hilar cholangiocarcinoma: The results of a nationwide, multicenter survey performed by the AFC-HC-2009 study group[J]. J Hepatol, 2012, 56(5): 1121-1128. DOI: 10.1016/j.jhep.2011.12.010.
    [25] MIYAZAKI M, KIMURA F, SHIMIZU H, et al. Extensive hilar bile duct resection using a transhepatic approach for patients with hepatic hilar bile duct diseases[J]. Am J Surg, 2008, 196(1): 125-129. DOI: 10.1016/j.amjsurg.2007.04.020.
    [26] XIONG J, NUNES QM, HUANG W, et al. Major hepatectomy in Bismuth types I and Ⅱ hilar cholangiocarcinoma[J]. J Surg Res, 2015, 194(1): 194-201. DOI: 10.1016/j.jss.2014.10.029.
    [27] CHEN YJ, ZHOU R. Application of mesohepatectomy with caudate lobectomy in hilar cholangiocarcinoma[J]. Chin J Dig Surg, 2021, 20(1): 52-58. DOI: 10.3760/cma.j.cn115610-20201116-00727.

    陈亚进, 周睿. 中肝叶联合尾状叶切除术在肝门部胆管癌中的应用[J]. 中华消化外科杂志, 2021, 20(1) : 52-58. DOI: 10.3760/cma.j.cn115610-20201116-00727.
    [28] IKEYAMA T, NAGINO M, ODA K, et al. Surgical approach to Bismuth type I and Ⅱ hilar cholangiocarcinomas: Audit of 54 consecutive cases[J]. Ann Surg, 2007, 246(6): 1052-1057. DOI: 10.1097/SLA.0b013e318142d97e.
    [29] WANG H, YAO XX, QIAO SX. Controversies over the extent of surgical resection for hilar cholangiocarcinoma and research advances in diagnosis and treatment[J]. J Clin Hepatol, 2020, 36(3): 704-707. DOI: 10.3969/j.issn.1001-5256.2020.03.053.

    汪宏, 姚小晓, 乔士兴. 肝门部胆管癌手术切除范围的争议及诊疗进展[J]. 临床肝胆病杂志, 2020, 36(3): 704-707. DOI: 10.3969/j.issn.1001-5256.2020.03.053.
    [30] NIMURA Y, HAYAKAWA N, KAMIYA J, et al. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus[J]. World J Surg, 1990, 14(4): 535-543; discussion 544. DOI: 10.1007/BF01658686.
    [31] MANSOUR JC, ALOIA TA, CRANE CH, et al. Hilar cholangiocarcinoma: Expert consensus statement[J]. HPB (Oxford), 2015, 17(8): 691-699. DOI: 10.1111/hpb.12450.
    [32] KIM SJ, KIM MJ, HAN JS, et al. Prediction of recurrence with KRAS mutational burden using ultrasensitive digital polymerase chain reaction of radial resection margin of resected pancreatic ductal adenocarcinoma[J]. Pancreas, 2019, 48(3): 400-411. DOI: 10.1097/MPA.0000000000001255.
  • 加载中
计量
  • 文章访问数:  148
  • HTML全文浏览量:  96
  • PDF下载量:  23
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-04-01
  • 录用日期:  2021-04-16
  • 出版日期:  2021-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回